Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2020

Lee Hye Won, Sa Jason K, Gualberto Antonio, Scholz Catherine, Sung Hyun Hwan, Jeong Byong Chang, Choi Han Yong, Kwon Ghee Young, Park Se Hoon

Abstract excerpt

PURPOSE: To assess the antitumor activity and safety of tipifarnib, a highly potent and selective farnesyltransferase inhibitor, we performed a phase II clinical trial in patients with advanced and refractory urothelial carcinoma harboring missense HRAS mutations. PATIENTS AND METHODS: A total of 245 adult patients with previously treated, advanced urothelial carcinoma entered the molecular screening program...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP-Activated Protein Kinase Kinases
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Neoplasm Metastasis

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinolones

Share to Urothelium

Source

Identifiers

PMID: 32636318
DOI: 10.1158/1078-0432.CCR-20-1246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.PMID 32636318Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder CancerSemantic proximity Read ↗

Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study.Semantic proximity Read ↗

Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas.Semantic proximity Read ↗

Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."Semantic proximity Read ↗

Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.Semantic proximity Read ↗

DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.Semantic proximity Read ↗

Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.Semantic proximity Read ↗

Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma.Semantic proximity Read ↗

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.Semantic proximity Read ↗

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Semantic proximity Read ↗

FGFR3 alteration sites and response rate to FGFR inhibitors in urothelial carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.